bisphosphonic acid acts as gamma/delta t cell activating antigen and has direct cytotoxic activity...

1
BioMed Central TIONAL INTERNA CANCER CELL Page 1 of 1 (page number not for citation purposes) Cancer Cell International Open Access Poster presentation Bisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cells J Schmidt 1 , Mv Lilienfeld-Toal 2 , MW Büchler 1 and A Märten* 1 Address: 1 Department of Surgery, University of Heidelberg, Germany and 2 Department of Internal Medicine I, University of Bonn, Germany Email: A Märten* - [email protected] * Corresponding author Background T cells bearing the Gamma9/Delta2 T cell receptor (TCR) constitute two to ten percent of peripheral blood T lym- phocytes. They have recently raised much interest as non- MHC restricted effector cells against a variety of tumors. Gamma/Delta T cells are known to be stimulated by phos- phoantigens without the need of professional antigen pre- senting cells. Furthermore, it is described that incubation with phosphoantigens increases their proliferation rate rapidly. Materials & Methods Apoptotic and anti-proliferative effects of two bisphos- phonates (pamidronate and zoledronic acid) against eight different ductal pancreatic carcinoma cell lines were measured by Annexin-V/PI stain and MTT assay. Gamma/ Delta T cells were enriched from peripheral blood of healthy donors and expanded by stimulation with anti- CD3 and IL-2. Cytotoxic activity of Gamma/Delta T cells of age of 14 days was tested against these cell lines. In the next step, we pulsed tumor cells prior to the 51 Cr release assay with bisphosphonates. Results Zoledronic acid induced even at lower concentrations inhibition of proliferation. Incubation with a 3 µM solu- tion inhibits proliferation to 11–93%. Cell lines suscepti- ble for this treatment had a higher apoptosis rate. Gamma/Delta T cells showed cytotoxic activity against pancreatic cell lines (cell lysis of 24–37% at an effector to target ratio of 80:1). Inhibition of proliferation correlated significantly with susceptibility against Gamma/Delta T cells (P < 0.003). Pulsing of target cells with bisphospho- nates prior to the cytotoxicity assay increased the lysis rate (41–87%). Discussion Zoledronic acid has even at concentrations which could be achieved by normal dosage an anti-proliferative and apoptotic effect. Cell lines which are susceptible for bisphosphonates were also susceptible for treatment with Gamma/Delta T cells. The efficacy of Gamma/Delta T cells could be further enhanced by pulsing tumor cells with bisphosphonates. Conclusion At least for some pancreatic carcinoma cells a bisphospho- nate-based therapy maybe useful, particular in combina- tion with adoptive transfer of Gamma/Delta T cells from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2 nd Annual Meeting Mainz, Germany, 6–7 May 2004 Published: 1 July 2004 Cancer Cell International 2004, 4(Suppl 1):S25 Received: 28 April 2004 <supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement> This article is available from: http://www.cancerci.com/content/4/S1/S35

Upload: j-schmidt

Post on 06-Jul-2016

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Bisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cells

BioMed CentralC

TIONALINTERNACANCER CELL

Page 1 of 1(page number not for citation purposes)

Cancer Cell International

Open AccessPoster presentationBisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cellsJ Schmidt1, Mv Lilienfeld-Toal2, MW Büchler1 and A Märten*1

Address: 1Department of Surgery, University of Heidelberg, Germany and 2Department of Internal Medicine I, University of Bonn, Germany

Email: A Märten* - [email protected]

* Corresponding author

BackgroundT cells bearing the Gamma9/Delta2 T cell receptor (TCR)constitute two to ten percent of peripheral blood T lym-phocytes. They have recently raised much interest as non-MHC restricted effector cells against a variety of tumors.Gamma/Delta T cells are known to be stimulated by phos-phoantigens without the need of professional antigen pre-senting cells. Furthermore, it is described that incubationwith phosphoantigens increases their proliferation raterapidly.

Materials & MethodsApoptotic and anti-proliferative effects of two bisphos-phonates (pamidronate and zoledronic acid) againsteight different ductal pancreatic carcinoma cell lines weremeasured by Annexin-V/PI stain and MTT assay. Gamma/Delta T cells were enriched from peripheral blood ofhealthy donors and expanded by stimulation with anti-CD3 and IL-2. Cytotoxic activity of Gamma/Delta T cellsof age of 14 days was tested against these cell lines. In thenext step, we pulsed tumor cells prior to the 51Cr releaseassay with bisphosphonates.

ResultsZoledronic acid induced even at lower concentrationsinhibition of proliferation. Incubation with a 3 µM solu-tion inhibits proliferation to 11–93%. Cell lines suscepti-ble for this treatment had a higher apoptosis rate.Gamma/Delta T cells showed cytotoxic activity againstpancreatic cell lines (cell lysis of 24–37% at an effector totarget ratio of 80:1). Inhibition of proliferation correlatedsignificantly with susceptibility against Gamma/Delta T

cells (P < 0.003). Pulsing of target cells with bisphospho-nates prior to the cytotoxicity assay increased the lysis rate(41–87%).

DiscussionZoledronic acid has even at concentrations which couldbe achieved by normal dosage an anti-proliferative andapoptotic effect. Cell lines which are susceptible forbisphosphonates were also susceptible for treatment withGamma/Delta T cells. The efficacy of Gamma/Delta T cellscould be further enhanced by pulsing tumor cells withbisphosphonates.

ConclusionAt least for some pancreatic carcinoma cells a bisphospho-nate-based therapy maybe useful, particular in combina-tion with adoptive transfer of Gamma/Delta T cells

from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual MeetingMainz, Germany, 6–7 May 2004

Published: 1 July 2004

Cancer Cell International 2004, 4(Suppl 1):S25

Received: 28 April 2004<supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement>

This article is available from: http://www.cancerci.com/content/4/S1/S35